Insider · CIK 0001180763
Simba Gill
Files at EVLO (Evelo Biosciences, Inc.), SER (Serina Therapeutics, Inc.), FHTX (Foghorn Therapeutics Inc.). First filing Nov 8, 2023, latest Nov 8, 2023.
In brief
Simba Gill files SEC Form 4 as director, CEO and president at EVLO (Evelo Biosciences, Inc.), and also at SER (Serina Therapeutics, Inc.), FHTX (Foghorn Therapeutics Inc.). Since Nov 8, 2023, Simba Gill has reported 0 open-market buys worth $0 and 1 open-market sell worth $57, the latest filed on Nov 8, 2023.
A track record needs three past buys with six months of prices behind them; Simba Gill has 0, so none is measured yet.
The newest scored trade: sold $57 of EVLO on Nov 8, 2023, filed Nov 8, 2023, scored 5 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EVLO: Evelo Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Evelo Biosciences, Inc. | $57 172 shares | -1% | - |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Feb 3, 2026 | SER Serina Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Feb 17, 2026 |
| Jun 17, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
| Nov 7, 2023 | EVLO Evelo Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +1,172 | - | - | 17,930 | Nov 8, 2023 |
| Nov 8, 2023 | EVLO Evelo Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -172 | $0.33 | $57 | 17,758 | Nov 8, 2023 |
| Nov 7, 2023 | EVLO Evelo Biosciences, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -1,172 | $0.00 | $0 | 15,236 | Nov 8, 2023 |
Questions about Simba Gill
Answered from the filings on this page, as of the latest one.
Is Simba Gill buying or selling?
Not in the last 12 months. Simba Gill's latest open-market trade on SEC Form 4 was sold $57 of EVLO on Nov 8, 2023.
How did Simba Gill's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Simba Gill has 0.
Where does Simba Gill file Form 4?
Simba Gill has filed Form 4 at EVLO (Evelo Biosciences, Inc.) as President & CEO; SER (Serina Therapeutics, Inc.); FHTX (Foghorn Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.